The content on this website is intended for healthcare professionals and is not intented to be professional medical advice. The Instructions for Use (IFU) for the product must therefore be consulted before use of any product. Please be aware that the product and/or an indication might not be approved in your country, e.g. US. Please contact your Bentley representative for further information.

Close
September 13, 2022

From left to right: Rainer Bregulla (Director R & D), Sebastian Büchert (CEO), Thomas Morawek (Arnold Schwarzenegger Impersonator), Hartmut Grathwohl (Director Operations), Andrew Brabner (Director Finance & IT),  Christian Bader (Director Quality & Market Access)

Bentley acquired the GoBack catheter

Bentley, a global leader in minimally invasive medical devices for vascular treatments based in the Medical Valley of Hechingen, has acquired the rights of the GoBack catheter from Upstream Peripheral Technologies (Caesarea, Israel).

This acquisition expands the company’s product portfolio, which is dedicated to improve the clinical outcomes of endovascular treatments, and because of this improving the patients’ quality of life.

“The acquisition of the GoBack catheter marks the start of inorganic growth for Bentley,” said Sebastian Büchert, Bentley's CEO. “We launched our first of six existing product families to the market in 2012 and have experienced significant growth since then. Now, only 10 years later we are able to acquire this very innovative product. This strategic move further completes our product offering to hospitals and physicians to the benefit of our joint patients.”

The GoBack catheter will simplify to “cross” and/or “re-entry” lesions in the arteries, which are for example occluded by heavily calcified plaque or stenosis. Its unique feature is a curved nickel-titan-alloy (nitinol) needle that can be manipulated by the physician using the device handle. Thanks to its small profile, the device can even be used in the smaller arteries in the lower leg.

“Bentley acquiring the GoBack makes me feel proud. I am sure that with Bentley’s global footprint more physicians will have access to the catheter,” said Dan Rottenberg, CEO of Upstream Peripheral Technologies. “Our vision is to save limbs and reduce the number of amputations. With Bentley’s strong network more patients will have access to such treatment.”

The GoBack catheter is CE marked and FDA cleared. The fact that the catheter also has FDA clearance will give Bentley the opportunity to explore the US market much quicker as initially planned. Launched in 2019, the device is now available in 23 countries. It is Bentley’s intention to extend the global availability to all of the 80 markets in which the company is already active.

Martijn Nugteren, Director Sales & Marketing, Bentley, says, “We will be really busy in the months ahead. Not only because we want to make the product commercially available in additional markets, but also due to the fact that we are going to rebrand the GoBack to BeBack. This is to make sure that our new product will be recognised as another leading product underneath Bentley’s brand umbrella.”

Currently produced in Israel and initially shipped from there, a production transfer to the Bentley production facility in Hechingen, Germany, will be completed by 2025.

 

For further information, check: www.bentley.global


About Bentley

Bentley was founded in 2009 by medical entrepreneurs Lars Sunnanväder and Miko Obradovic. The company has seen substantial growth since the launch of its first product in 2012, and today operates a global distribution network in more than 80 countries. The seven top-line products in Bentley’s portfolio are:

  • BeGraft coronary (2012)
  • BeGraft peripheral: 1st generation (2013); 2nd generation (2015)
  • BeSmooth peripheral (2014)
  • BeGraft aortic (2016)
  • BeGraft PLUS (2017)
  • BeYond (2020)
  • GoBack/BeBack (2022)

 

About Upstream Peripheral Technologies

Upstream Peripheral Technologies is a privately held company, produces the GoBack Catheter to treat chronic total occlusions in angioplasty procedures. The company's mission is to ensure that no patient is left untreated, and has helped physicians save thousands of patients from unnecessary leg amputations.

 

Contact: Matthias Bleesen, Communication & Event Coordinator, m.bleesen@bentley.global, +49 7471 984 995 631

International

Customer service:
+49 7471 984 995 10

Contact

Bentley InnoMed GmbH

Lotzen├Ącker 3
72379 Hechingen / Germany
+49 7471 984 995 10

info@bentley.global

www.bentley.global

United States

Customer service:
+1 770 295 2288

Contact

Bentley US Inc.

2220 Northmont Pkwy. Suite 250
Duluth, GA 30096 / USA
+1 770 295 2288

info@bentley.global

www.bentley.global